ESTEVE's Strategic Expansion and Sustained Growth

In 2025, ESTEVE achieved significant growth, driven by strategic acquisitions in both its pharmaceutical and CDMO sectors. The company reported a 14% increase in net revenues and a 19% rise in EBITDA, attributed to robust strategy execution. Key acquisitions included the Infusion Business Unit of TerSera and Regis Technologies in the USA, enhancing ESTEVE's capabilities and portfolio.

ESTEVE's dual-engine business model facilitated the launch of eight new products, emphasizing oncology and endocrinology. Additionally, the company's B Corp Certification underscores its commitment to ESG standards, integrating these into its operations and decision-making processes.

Looking forward, ESTEVE aims for €1 billion in net revenue by 2027, focusing on innovation and global expansion, particularly in the US and EU markets. Investments in product and process development reached €49 million in 2025, highlighting ESTEVE's dedication to long-term growth and sustainability.